Clearmind Medicine (CMND) Delivers Positive AUD Trial Data Amid New Depression Patent – Nov. 18, 2025
Clearmind Medicine Inc. is back in the spotlight today after releasing positive top-line results from the first cohort of its FDA‑approved Phase I/IIa clinical trial for CMND‑100 in alcohol use disorder. The update lands just one day after the company highlighted a new Israeli patent filing for a non‑hallucinogenic depression therapy, and as a fresh equity offering is expected to close around today’s date. GlobeNewswire+2GlobeNewswire+2
